Page 23 - Haematologica Vol. 109 - July 2024

EDITORIAL
O. Al-Sawaf
leukemia/small lymphocytic lymphoma. J Natl Compr Canc
Netw. 2023;21(5.5):563-566.
4. Shadman M, Flinn IW, Levy MY, et al. Zanubrutinib in patients
with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Lancet Haematol. 2023;10(1):e35-e45.
5. Rogers KA, Thompson PA, Allan JN, et al. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/ refractory chronic lymphocytic leukemia. Haematologica. 2021;106(9):2364-2373.
6. Wang H, Zhang W, Yang J, Zhou K. The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma. Hematol Oncol. 2021;39(5):605-615.
7. Blombery P, Thompson ER, Lew TE, et al. Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance. Blood Adv. 2022;6(20):5589-5592.
8. Wang E, Mi X, Thompson MC, et al. Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors. N Engl J Med. 2022;386(8):735-743.
Haematologica | 109 July 2024
2037